Prospects of plasmapheresis for patients with severe COVID-19

Gilmutdinova, Ilmira R.; Yakovlev, Maxim Yu.; Eremin, Petr S.; Fesun, Anatoliy D.

doi:10.4081/ejtm.2020.9165

Cited by 10 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In December 2019, an unprecedented pneumonia case was first reported in Wuhan, a city in China, and quickly spread around the world [ 1 ]. The Coronavirus Study Group (CSG) of the International Committee on Taxonomy of Viruses (ICTV) officially named the novel coronavirus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on 11 February 2020 [ 2 ]. The surface of SARS-CoV-2 is mainly composed of four structure proteins, including spike glycoprotein (S), which specifically binds to host cell receptors, membrane protein (M), which is related to envelope formation, envelope small membrane protein (E), and nucleoprotein, which is related to viral assembly (N).…”

Section: Introductionmentioning

confidence: 99%

Recent Advances of Representative Optical Biosensors for Rapid and Sensitive Diagnostics of SARS-CoV-2

Lin

et al. 2022

Biosensors

View full text Add to dashboard Cite

The outbreak of Corona Virus Disease 2019 (COVID-19) has again emphasized the significance of developing rapid and highly sensitive testing tools for quickly identifying infected patients. Although the current reverse transcription polymerase chain reaction (RT-PCR) diagnostic techniques can satisfy the required sensitivity and specificity, the inherent disadvantages with time-consuming, sophisticated equipment and professional operators limit its application scopes. Compared with traditional detection techniques, optical biosensors based on nanomaterials/nanostructures have received much interest in the detection of SARS-CoV-2 due to the high sensitivity, high accuracy, and fast response. In this review, the research progress on optical biosensors in SARS-CoV-2 diagnosis, including fluorescence biosensors, colorimetric biosensors, Surface Enhancement Raman Scattering (SERS) biosensors, and Surface Plasmon Resonance (SPR) biosensors, was comprehensively summarized. Further, promising strategies to improve optical biosensors are also explained. Optical biosensors can not only realize the rapid detection of SARS-CoV-2 but also be applied to judge the infectiousness of the virus and guide the choice of SARS-CoV-2 vaccines, showing enormous potential to become point-of-care detection tools for the timely control of the pandemic.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent Advances of Representative Optical Biosensors for Rapid and Sensitive Diagnostics of SARS-CoV-2

Lin

et al. 2022

Biosensors

View full text Add to dashboard Cite

show abstract

“…Therapeutic plasma exchange (TPE) is an extracorporeal treatment performed by filtrating a volume of plasma equivalent to the estimated plasma volume that selectively removes circulating pathogenetic substances, such as autoreactive antibodies, immune complexes, paraproteins, lipoproteins, and inflammatory mediators like cytokines. TPE has been applied to manage different critical diseases, including the acute respiratory distress syndrome (ARDS) (10), pneumonia and respiratory failure from H1N1 influenza A virus (11), Kawasaki disease (12), and sepsis, effectively reducing the elevated levels of cytokines and inflammatory mediators, avoiding lethal complications as septic shock, pulmonary embolism, renal injury, or disseminated intravascular coagulation (2,10,(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

On Therapeutic Plasma Exchange Against Severe COVID-19-Associated Pneumonia: An Observational Clinical Study

et al. 2022

View full text Add to dashboard Cite

BackgroundThere is a risk of novel mutations of SARS-CoV-2 that may render COVID-19 resistant to most of the therapies, including antiviral drugs and vaccines. The evidence around the application of therapeutic plasma exchange (TPE) for the management of critically ill patients with COVID-19 is still provisional, and further investigations are needed to confirm its eventual beneficial effects.AimsTo assess the effect of TPE on the risk of mortality in patients with COVID-19-associated pneumonia, using three statistical procedures to rule out any threats to validity.MethodsWe therefore carried out a single-centered retrospective observational non-placebo-controlled trial enrolling 73 inpatients from Baqiyatallah Hospital in Tehran (Iran) with the diagnosis of COVID-19-associated pneumonia confirmed by real-time polymerase chain reaction (RT-qPCR) on nasopharyngeal swabs and high-resolution computerized tomography chest scan. These patients were broken down into two groups: Group 1 (30 patients) receiving standard care (corticosteroids, ceftriaxone, azithromycin, pantoprazole, hydroxychloroquine, lopinavir/ritonavir), and Group 2 (43 patients) receiving the above regimen plus TPE (replacing 2 l of patients' plasma by a solution, 50% of normal plasma, and 50% of albumin at 5%) administered according to various time schedules. The follow-up time was 30 days and all-cause mortality was the endpoint.ResultsDeaths were 6 (14%) in Group 2 and 14 (47%) in Group 1. However, different harmful risk factors prevailed among patients not receiving TPE rather than being equally split between the intervention and control group. We used an algorithm of structural equation modeling (of STATA) to summarize a large pool of potential confounders into a single score (called with the descriptive name “severity”). Disease severity was lower (Wilkinson rank-sum test p < 0.001) among patients with COVID-19 undergoing TPE (median: −2.82; range: −5.18; 7.96) as compared to those not receiving TPE (median: −1.35; range: −3.89; 8.84), confirming that treatment assignment involved a selection bias of patients according to the severity of COVID-19 at hospital admission. The adjustment for confounding was carried out using severity as the covariate in Cox regression models. The univariate hazard ratio (HR) of 0.68 (95%CI: 0.26; 1.80; p = 0.441) for TPE turned to 1.19 (95%CI: 0.43; 3.29; p = 0.741) after adjusting for severity.ConclusionsIn this study sample, the lower mortality observed among patients receiving TPE was due to a lower severity of COVID-19 rather than the TPE effects.

show abstract

“…Extracorporeal hemocorrection has a particularly good track record [4]. For example, therapeutic plasmapheresis can be efficient during prophylaxis, treatment, and rehabilitation after various diseases and injuries-its major effects are associated with the removal of endo-and exotoxins including the products of lipid peroxidation [5]. Its effects are also related to a draining effect resulting from an enhanced inflow of interstitial fluid (containing products of pathometabolism) into the bloodstream within a concentration gradient.…”

Section: Introductionmentioning

confidence: 99%

The use of therapeutic plasmapheresis in preventive and sports medicine

et al. 2022

View full text Add to dashboard Cite

Maintenance of active longevity, preservation of physical activity, and prevention of decreased mobility associated with injury or age of patients are among the most urgent tasks for modern healthcare. The suppression of pathological processes and activation of defense systems at the cellular and organismal levels are the main routes for solving these problems. Several initial anti-aging therapy approaches are detoxification, rheocorrection, and immunocorrection. In these areas, methods of extracorporeal hemocorrection, in particular, therapeutic plasmapheresis, are effective. This study aimed to evaluate the effectiveness of hardware plasmapheresis with albumin compensation by assessing the dynamics of circulating age-related biomarker levels in randomly selected patients. Twenty human subjects of both sexes aged 40–55 years with an increase in one or more aging-related biomarkers participated in this study. The patients were randomly divided into two groups with ten people each. Patients from Group 1 underwent therapeutic plasmapheresis with albumin replacement (four procedures with a 2-day interval). Patients from Group 2 were offered plasmapheresis treatment with saline replacement. The levels of aging-related biomarkers were determined in the blood of patients before and 30 days after starting treatment. Preliminary data showed that plasmapheresis with albumin replacement in randomly selected male and female patients was accompanied by normalization of the selected aging biomarkers. Thirty days after the start of the plasmapheresis treatment, a decrease in both biological and phenotypic age was determined. Further studies are needed to investigate the effects of nutritional factors on aging biomarkers with and without plasmapheresis treatment. Based on the obtained results, recommendations will be made on the use of plasmapheresis in preventive and sports medicine. The use of this method will help reduce the biological age of patients and, as a result, reduce the risks of developing age-related diseases and disabilities and contribute to prolonging life and improving its quality.

show abstract

Prospects of plasmapheresis for patients with severe COVID-19

Cited by 10 publications

References 27 publications

Recent Advances of Representative Optical Biosensors for Rapid and Sensitive Diagnostics of SARS-CoV-2

Recent Advances of Representative Optical Biosensors for Rapid and Sensitive Diagnostics of SARS-CoV-2

On Therapeutic Plasma Exchange Against Severe COVID-19-Associated Pneumonia: An Observational Clinical Study

The use of therapeutic plasmapheresis in preventive and sports medicine

Contact Info

Product

Resources

About